Home/ Stocks/ ZYME

Zymeworks Inc.

ZYME XNAS

$23.54 +0.01 (+0.04%) ▲ 15-min delayed

Open

$24.10

High

$24.76

Low

$23.18

Volume

578.1K

Market Cap

$1.70B

About Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 264 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$2.41M	$-44,162,000	$-0.59
FY 2025	$105.97M	$-81,130,000	$-1.08
Q3 2025	$27.61M	$-19,602,000	$-0.26
Q2 2025	$48.73M	$2.32M	$0.03

Earnings & Analyst Ratings

Next Earnings: Wed, Nov 4, 2026

Calendar →

Related Market News

No specific coverage for ZYME yet. Check out our latest market news or earnings calendar.

Get ZYME Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Zymeworks Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.